Core Insights - Baron Health Care Fund reported a 5.39% increase in Q3 2025, slightly outperforming the Russell 3000 Health Care Index which gained 5.05% [1] - The fund's performance was impacted by stock selection and negative effects from active sub-industry allocations and cash holdings during a rising market [1] Group 1: AbbVie Inc. Overview - AbbVie Inc. is a research-based biopharmaceutical company with a market capitalization of $385.18 billion and a stock price of $218.04 as of October 31, 2025 [2] - The one-month return for AbbVie was -5.28%, while it gained 8.76% over the last 52 weeks [2] Group 2: Growth Drivers and Financial Performance - AbbVie has key growth drivers including Skyrizi and Rinvoq, with no major patent expirations until the mid-2030s, following a recent settlement that delayed generic competition for Rinvoq to 2037 [3] - The company is expected to achieve high single-digit top-line growth and low double-digit bottom-line growth for many years [3] Group 3: Market Position and Hedge Fund Interest - AbbVie was held by 89 hedge fund portfolios at the end of Q2 2025, an increase from 86 in the previous quarter [4] - AbbVie reported total net revenues of $15.4 billion in Q2 2025, exceeding expectations by over $400 million [4]

Core Viewpoint - AbbVie Inc. (NYSE:ABBV) is a prominent stock being discussed during the latest earnings season, with a notable increase in share price of 21% year-to-date [1]. Group 1: Investment Recommendations - Jason Snipe, Founder and Chief Investment Officer of Odyssey Capital Advisors, has recommended investors to "stay long" on AbbVie Inc. [1]. - Carillon Eagle Growth & Income Fund noted that AbbVie Inc.'s shares were a detractor for their portfolio in Q2 2025, primarily due to the underperformance of the broader biopharmaceutical industry [2]. Group 2: Market Context - The biopharmaceutical industry is currently facing pressures from policy threats related to tariffs and drug pricing proposals from the Trump administration, impacting AbbVie Inc.'s performance [2]. - Despite the challenges, there is an acknowledgment of AbbVie Inc.'s potential as an investment, although some believe that AI stocks may offer greater promise for higher returns with limited downside risk [2].

Core Insights - September was a challenging month for Dividend Aristocrats, with the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) experiencing a loss of 1.68% [1] Group 1: Performance Analysis - The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) finished September with a loss of 1.68% [1] - In comparison, the SPDR S&P 500 ETF's performance was not detailed, but the context suggests a broader market trend affecting dividend stocks [1]

Core Viewpoint - AbbVie's latest earnings release did not meet investor expectations, leading to a stock price decline of over 4%, contrasting with a slight gain in the S&P 500 index [1] Financial Performance - AbbVie reported third-quarter revenue of approximately $15.78 billion, reflecting a 9% year-over-year increase, driven by strong sales of blockbuster drugs [2] - The company achieved a net income of $3.3 billion ($1.86 per share) on a non-GAAP basis, up from $2.3 billion in the same quarter of 2024, surpassing analyst estimates for both revenue and adjusted net income [3] Management Commentary - CEO Robert Michael highlighted the significant momentum in key areas of AbbVie's portfolio and emphasized progress in advancing the pipeline and investing in innovation for long-term growth [4] Guidance and Market Reaction - AbbVie raised its adjusted net income guidance for 2025 to a range of $10.61 to $10.65 per share, although this is below the consensus estimate of $10.86 [6]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - AbbVie Inc. raised its full-year profit forecast due to strong demand for its psoriasis treatment Skyrizi, leading to third-quarter sales that exceeded expectations, although shares fell over 4% in intra-day trading [1] Financial Performance - For the quarter ending in September, AbbVie reported a net revenue increase of 9.1% year-over-year, reaching $15.78 billion, driven by strong sales of Skyrizi and Rinvoq [2] - Adjusted earnings per share for the quarter were $1.86, a decrease from $4.86 a year earlier, but above Bloomberg's consensus estimate of $1.77 [2] Product Performance - The growth in immunology products helped mitigate the decline in Humira, which has faced significant competition from lower-cost biosimilars since 2023 [3] - Rinvoq generated $5.97 billion in revenue in 2024, representing approximately half of AbbVie's total sales, with expectations that Rinvoq and Skyrizi will together contribute about $31 billion in revenue by 2027 [3]

An updated edition of the September 01, 2025, article.The global population is aging at an unprecedented pace, fundamentally changing how healthcare systems, corporations and investors plan for long-term growth. As highlighted in the World Health Organization’s 2024 update, the population aged 60 and above surpassed the number of children under five for the first time in 2020 — a demographic turning point with far-reaching implications. By 2050, nearly 22% of people worldwide will be over the age of 60, wit ...

For the quarter ended September 2025, AbbVie (ABBV) reported revenue of $15.78 billion, up 9.1% over the same period last year. EPS came in at $1.86, compared to $3.00 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $15.59 billion, representing a surprise of +1.2%. The company delivered an EPS surprise of +5.08%, with the consensus EPS estimate being $1.77.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

By Patrick Wingrove and Puyaan Singh (Reuters) -AbbVie said on Friday the Trump administration was pushing for steeper cuts in this year's Medicare drug price negotiations, which in 2024 yielded discounts of as much as 79%. AbbVie's irritable bowel syndrome drug Linzess and antipsychotic medication Vraylar were among the 15 drugs targeted this year for Medicare price negotiations that end on Saturday. The company said these cuts, which have yet to be made public and will take effect in 2027, would not a ...

AbbVie Inc. (NYSE:ABBV) reported third-quarter 2025 sales of $15.78 billion on Friday, beating the consensus of $15.59 billion.Sales increased 9.1% on a reported basis or 8.4% on an operational basis. The company reported adjusted earnings of $1.86 per share, down 38%, beating the consensus of $1.79.Dividend: AbbVie increased its quarterly dividend from $1.64 per share to $1.73.“AbbVie continues to deliver outstanding results, with significant momentum across key areas of our portfolio. We are also making g ...